Biocon Limited

Biocon Limited announced changes to its board and statutory auditors following its 48th Annual General Meeting on August 6, 2026. Eric Vivek Mazumdar was re-appointed as a director liable to retire by rotation, while Nicholas Robert Haggar retired as an Independent Director. The company also appointed S.R. Batliboi & Associates LLP as its statutory auditors for a five-year term, replacing B S R & Co. LLP.

Biocon Limited announced changes to its board and statutory auditors following its 48th Annual General Meeting on August 6, 2026. Mr. Eric Vivek Mazumdar was re-appointed as a director liable to retire by rotation, while B S R & Co. LLP’s term as statutory auditors expired. S.R. Batliboi & Associates LLP was appointed as the new statutory auditors for a five-year term, concluding after the 53rd AGM in 2031, and Mr. Nicholas Robert Haggar retired as an Independent Director.

Biocon Limited announced changes to its board and statutory auditors following its 48th Annual General Meeting on August 6, 2026. Mr. Eric Vivek Mazumdar was re-appointed as a director liable to retire by rotation, while B S R & Co. LLP’s term as statutory auditors expired. S.R. Batliboi & Associates LLP was appointed as the new statutory auditors for a five-year term, concluding after the 53rd AGM in 2031, and Mr. Nicholas Robert Haggar retired as an Independent Director.

Biocon Ltd share price ticked higher by 0.51% to Rs 425.15. The Company's net profit plunged by 31.12% to Rs 136.8 crore, while revenue from operations eased by 4.29% to Rs 4291.8 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, rising 5.25%. It has improved by 0.41% over last one week and climbed by 11.45% in last one month while the market capitalization of Biocon Ltd has softened by 1.32% and 11.72% in the same period respectively. Profit before tax (PBT) of Biocon Ltd stood at Rs 127.6 crore in Q2 FY26, surging by 31.68% year-on-year, and nosediving by 48.44% quarter-on-quarter. EBITDA came in at Rs 793 crore, jumping 15.49% YoY and tumbling by 18.09% sequentially. Total expenses posted a minor rise of 0.66% to Rs 4036.2 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 1424.1 crore, inching up 4.81% YoY, while employee benefits expense was at Rs 916.1 crore, ticking higher by 0.44% YoY. For the TTM ended FY26, revenue from operations rose 11.48% to Rs 16779.9 crore, while net profit tanked by 74.20% to Rs 368.8 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 222680% to Rs 3112.8 crore, and PBT collapsed by 76.26% to Rs 447.9 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1994.0 crore in FY26, as against Rs 4061.2 crore in FY25. Biocon Ltd jumped 11.16% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 3.20% during the same period.

Biocon Limited announced the commercial launch of Yesafili™ (aflibercept), a biosimilar to Regeneron’s Eylea® 2 mg, in the United States, effective August 3, 2026. The product, which received U.S. Food and Drug Administration approval and interchangeable designation in May 2024, is indicated for the treatment of conditions such as age-related macular degeneration and diabetic macular edema, and is expected to benefit an estimated 19.8 million Americans.

Biocon will hold a meeting of the Board of Directors of the Company on 5 August 2026.

Biocon has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee' (insulin glargine) at its insulin manufacturing facility in Malaysia. Supplies to Europe from this line are expected to begin from Q2FY27.

Mylan sold around 9.19 crore shares, representing its entire 5.64% stake, at Rs 400 per share across the BSE and NSE. The block deal witnessed strong participation from domestic and foreign institutional investors. ICICI Prudential Mutual Fund emerged as the largest buyer, acquiring 3.69 crore shares (2.26% stake). HDFC Mutual Fund and Kotak Mahindra Mutual Fund each purchased 1.16 crore shares (0.71% stake), while SBI Mutual Fund acquired 50 lakh shares (0.31% stake). ICICI Prudential Life Insurance bought 25 lakh shares (0.15% stake). Aditya Birla Sun Life Mutual Fund, Franklin Templeton Mutual Fund and Mirae Asset Mutual Fund acquired 18.75 lakh shares (0.12% stake) each, while Tata Mutual Fund purchased 6.26 lakh shares (0.04% stake). Other investors, including Axis Mutual Fund, UTI Mutual Fund, Mahindra Mutual Fund, IDFC Mutual Fund, HDFC Life Insurance, Bajaj Life Insurance, Norges Bank, Goldman Sachs Bank Europe, Morgan Stanley Asia Singapore, Societe Generale, Vanguard Emerging Markets Shares Index Fund, WhiteOak Capital Mutual Fund, Authum Investment & Infrastructure, Abakkus Growth Fund, Canara Robeco Mutual Fund and Eastspring Investments Asian Low Volatility Equity Fund, each acquired 6.26 lakh shares (0.04% stake). Citigroup Global Markets Singapore and BNP Paribas Arbitrage purchased 7.50 lakh shares (0.05% stake) each. Mylan's relationship with Biocon began in 2009, when the companies entered into a global collaboration to develop and commercialise biosimilars. The partnership later expanded to generic insulin analogues. Mylan became a shareholder in Biocon in January 2026 after the company issued shares as part of the acquisition of Viatris' stake in Biocon Biologics. The latest transaction marks Mylan's complete exit from Biocon. As of 30 June 2026, Biocon's promoters held a 44.67% stake in the company, while Mylan owned 5.64%. Biocon is a global biopharmaceutical company focused on developing affordable therapies for chronic diseases, including diabetes, cancer and autoimmune disorders. On a consolidated basis, the company's net profit declined 63.4% YoY to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25. Revenue from operations increased 2.26% YoY to Rs 4,517 crore during the quarter. Shares of Biocon were down 0.70% at Rs 434.25 on the NSE. Powered by Capital Market - Live

Nuvoco Vistas Corporation Ltd, Cipla Ltd, Aadhar Housing Finance Ltd, Alkem Laboratories Ltd are among the other stocks to see a surge in volumes on BSE today, 14 July 2026.Biocon Ltd saw volume of 473.28 lakh shares by 10:46 IST on BSE, a 224.63 fold spurt over two-week average daily volume of 2.11 lakh shares. The stock increased 7.08% to Rs.439.60. Volumes stood at 5.05 lakh shares in the last session.Nuvoco Vistas Corporation Ltd clocked volume of 8.72 lakh shares by 10:46 IST on BSE, a 56.34 times surge over two-week average daily volume of 15478 shares. The stock gained 7.81% to Rs.340.35. Volumes stood at 39713 shares in the last session.Cipla Ltd notched up volume of 8.18 lakh shares by 10:46 IST on BSE, a 17.21 fold spurt over two-week average daily volume of 47526 shares. The stock rose 1.42% to Rs.1,447.00. Volumes stood at 20923 shares in the last session.Aadhar Housing Finance Ltd notched up volume of 7.5 lakh shares by 10:46 IST on BSE, a 5.79 fold spurt over two-week average daily volume of 1.30 lakh shares. The stock slipped 2.50% to Rs.522.40. Volumes stood at 7.09 lakh shares in the last session.Alkem Laboratories Ltd notched up volume of 1.9 lakh shares by 10:46 IST on BSE, a 5.3 fold spurt over two-week average daily volume of 35790 shares. The stock slipped 0.28% to Rs.5,559.15. Volumes stood at 39767 shares in the last session.Powered by Capital Market - Live

Trading volumes surged significantly during the session. On the BSE, 4.72 crore shares changed hands compared with the three-month average of 2.49 lakh shares. On the NSE, 2.17 crore shares were traded, well above the three-month average of 41.40 lakh shares. According to media reports, U.S.-based Viatris-owned Mylan was looking to sell its entire 5.6% stake in the biotechnology company through block deals worth around Rs 3,481 crore. The transaction would mark Mylan's complete exit from Biocon after a 17-year partnership. The block deal was reportedly launched at a floor price of Rs 378.50 per share, a discount of 7.9% to Biocon's Monday closing price on the NSE. Mylan partnered with Biocon in 2009 to develop and commercialise biosimilars, later expanding the alliance to generic insulin analogues. It became a Biocon shareholder in January 2026 after Biocon issued shares as part of the acquisition of Viatris' stake in Biocon Biologics. The latest block deal would bring Mylan's association with Biocon to an end. As on June 2026, promoters held 44.67% stake in Biocon. Mylan Inc. held 5.64% in the company. Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. On a consolidated basis, the company's net profit declined 63.4% year-on-year to Rs 126 crore in Q4 FY26 from Rs 344 crore in Q4 FY25. Revenue from operations increased 2.26% YoY to Rs 4,517 crore during the quarter. Powered by Capital Market - Live